Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helga Sanner

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
The Journal of Rheumatology|February 2, 2022
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild RegistryGabriella Giancane, Riccardo Papa, Sebastiaan Vastert, et al.
Rheumatology (Oxford, England)|February 10, 2025
Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providersMatthew A Sherman, Rebecca Nicolai, Emily K Datyner, et al.
Arthritis Research & Therapy|April 9, 2020
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication CommitteeGabriella Giancane, Joost F Swart, Elio Castagnola, et al.
The Journal of Pediatrics|August 16, 2017
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation SyndromeFrancesca Minoia, Francesca Bovis, Sergio Davì, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2014
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patientsFrancesca Minoia, Sergio Davì, AnnaCarin Horne, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 7, 2017
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|October 29, 2017
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|May 23, 2025
Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task forceAngelo Ravelli, Silvia Rosina, Jayne M MacMahon, et al.
RMD Open|November 28, 2017
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportMatteo Bottai, Anna Tjärnlund, Giola Santoni, et al.
Rheumatology International|July 8, 2024
A protocol for scoping reviews on the role of whole-body and dedicated body-part magnetic resonance imaging for assessment of adult and juvenile idiopathic inflammatory myopathiesMickael Essouma, Daniel Brito de Araujo, Jessica Day, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Rheumatology|February 2, 2022
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild RegistryGabriella Giancane, Riccardo Papa, Sebastiaan Vastert, et al.
Rheumatology (Oxford, England)|February 10, 2025
Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providersMatthew A Sherman, Rebecca Nicolai, Emily K Datyner, et al.
Arthritis Research & Therapy|April 9, 2020
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication CommitteeGabriella Giancane, Joost F Swart, Elio Castagnola, et al.
The Journal of Pediatrics|August 16, 2017
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation SyndromeFrancesca Minoia, Francesca Bovis, Sergio Davì, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2014
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patientsFrancesca Minoia, Sergio Davì, AnnaCarin Horne, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 7, 2017
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|October 29, 2017
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsIngrid E Lundberg, Anna Tjärnlund, Matteo Bottai, et al.
Annals of the Rheumatic Diseases|May 23, 2025
Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task forceAngelo Ravelli, Silvia Rosina, Jayne M MacMahon, et al.
RMD Open|November 28, 2017
EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportMatteo Bottai, Anna Tjärnlund, Giola Santoni, et al.
Rheumatology International|July 8, 2024
A protocol for scoping reviews on the role of whole-body and dedicated body-part magnetic resonance imaging for assessment of adult and juvenile idiopathic inflammatory myopathiesMickael Essouma, Daniel Brito de Araujo, Jessica Day, et al.
Pageof 6